|
1
|
Menna P, Recalcati S, Cairo G and Minotti
G: An introduction to the metabolic determinants of anthracycline
cardiotoxicity. Cardiovasc Toxicol. 7:80–85. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lipshultz SE, Karnik R, Sambatakos P,
Franco VI, Ross SW and Miller TL: Anthracycline-related
cardiotoxicity in childhood cancer survivors. Curr Opin Cardiol.
29:103–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spallarossa P, Garibaldi S, Altieri P,
Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero
A, Patrone F, et al: Carvedilol prevents doxorubicin-induced free
radical release and apoptosis in cardiomyocytes in vitro. J Mol
Cell Cardiol. 37:837–846. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee DH, Kim S and Nam KS: Protective
effects of deep sea water against doxorubicin-induced
cardiotoxicity in H9c2 cardiac muscle cells. Int J Oncol.
45:2569–2575. 2014.PubMed/NCBI
|
|
5
|
Al-Harthi SE, Alarabi OM, Ramadan WS,
Alaama MN, Al-Kreathy HM, Damanhouri ZA, Khan LM and Osman AM:
Amelioration of doxorubicin-induced cardiotoxicity by resveratrol.
Mol Med Rep. 10:1455–1460. 2014.PubMed/NCBI
|
|
6
|
Goyal SN, Mahajan UB, Chandrayan G,
Kumawat VS, Kamble S, Patil P, Agrawal YO, Patil CR and Ojha S:
Protective effect of oleanolic acid on oxidative injury and
cellular abnormalities in doxorubicin induced cardiac toxicity in
rats. Am J Transl Res. 8:60–69. 2016.PubMed/NCBI
|
|
7
|
Renaud J, Bournival J, Zottig X and
Martinoli MG: Resveratrol protects DAergic PC12 cells from high
glucose-induced oxidative stress and apoptosis: Effect on p53 and
GRP75 localization. Neurotox Res. 25:110–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu MH, Yuan C, He J, Tan TP, Wu SJ, Fu
HY, Liu J, Yu S, Chen YD, Le QF, et al: Resveratrol protects PC12
cells from high glucose-induced neurotoxicity via PI3K/Akt/FoxO3a
pathway. Cell Mol Neurobiol. 35:513–522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tatlidede E, Sehirli O, Velioğlu-Oğünc A,
Cetinel S, Yeğen BC, Yarat A, Süleymanoğlu S and Sener G:
Resveratrol treatment protects against doxorubicin-induced
cardiotoxicity by alleviating oxidative damage. Free Radic Res.
43:195–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shankar S, Singh G and Srivastava RK:
Chemoprevention by resveratrol: Molecular mechanisms and
therapeutic potential. Front Biosci. 12:4839–4854. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rezk YA, Balulad SS, Keller RS and Bennett
JA: Use of resveratrol to improve the effectiveness of cisplatin
and doxorubicin: Study in human gynecologic cancer cell lines and
in rodent heart. Am J Obstet Gynecol. 194:e23–e26. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park DG: Antichemosensitizing effect of
resveratrol in cotreatment with oxaliplatin in HCT116 colon cancer
cell. Ann Surg Treat Res. 86:68–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y: Molecular links between caloric
restriction and Sir2/SIRT1 Activation. Diabetes Metab J.
38:321–329. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bitterman KJ, Anderson RM, Cohen HY,
Latorre-Esteves M and Sinclair DA: Inhibition of silencing and
accelerated aging by nicotinamide, a putative negative regulator of
yeast sir2 and human SIRT1. J Biol Chem. 277:45099–45107. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alcendor RR, Gao S, Zhai P, Zablocki D,
Holle E, Yu X, Tian B, Wagner T, Vatner SF and Sadoshima J: Sirt1
regulates aging and resistance to oxidative stress in the heart.
Circ Res. 100:1512–1521. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamamoto T and Sadoshima J: Protection of
the heart against ischemia/reperfusion by silent information
regulator 1. Trends Cardiovasc Med. 21:27–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luo J, Nikolaev AY, Imai S, Chen D, Su F,
Shiloh A, Guarente L and Gu W: Negative control of p53 by Sir2alpha
promotes cell survival under stress. Cell. 107:137–148. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen CJ, Yu W, Fu YC, Wang X, Li JL and
Wang W: Resveratrol protects cardiomyocytes from hypoxia-induced
apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res
Commun. 378:389–393. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo R, Lin J, Xu W, Shen N, Mo L, Zhang C
and Feng J: Hydrogen sulfide attenuates doxorubicin-induced
cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells.
Int J Mol Med. 31:644–650. 2013.PubMed/NCBI
|
|
20
|
Shukla S, Rizvi F, Raisuddin S and Kakkar
P: FoxO proteins' nuclear retention and BH3-only protein Bim
induction evoke mitochondrial dysfunction-mediated apoptosis in
berberine-treated HepG2 cells. Free Radic Biol Med. 76:185–199.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li F, Qu H, Cao HC, Li MH, Chen C, Chen
XF, Yu B, Yu L, Zheng LM and Zhang W: Both FOXO3a and FOXO1 are
involved in the HGF-protective pathway against apoptosis in
endothelial cells. Cell Biol Int. 39:1131–1137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Angsutararux P, Luanpitpong S and
Issaragrisil S: Chemotherapy-Induced Cardiotoxicity: Overview of
the Roles of Oxidative Stress. Oxid Med Cell Longev.
2015:7956022015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Wang XL, Chen HL, Wu D, Chen JX,
Wang XX, Li RL, He JH, Mo L, Cen X, et al: Ghrelin inhibits
doxorubicin cardiotoxicity by inhibiting excessive autophagy
through AMPK and p38-MAPK. Biochem Pharmacol. 88:334–350. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo R, Wu K, Chen J, Mo L, Hua X, Zheng D,
Chen P, Chen G, Xu W and Feng J: Exogenous hydrogen sulfide
protects against doxorubicin-induced inflammation and cytotoxicity
by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells. Cell
Physiol Biochem. 32:1668–1680. 2013.PubMed/NCBI
|
|
25
|
Das DK, Mukherjee S and Ray D: Erratum to:
Resveratrol and red wine, healthy heart and longevity. Heart Fail
Rev. 16:425–435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oktem G, Uysal A, Oral O, Sezer ED,
Olukman M, Erol A, Akgur SA and Bilir A: Resveratrol attenuates
doxorubicin-induced cellular damage by modulating nitric oxide and
apoptosis. Exp Toxicol Pathol. 64:471–479. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Danz ED, Skramsted J, Henry N, Bennett JA
and Keller RS: Resveratrol prevents doxorubicin cardiotoxicity
through mitochondrial stabilization and the Sirt1 pathway. Free
Radic Biol Med. 46:1589–1597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shang L, Zhou H, Xia Y, Wang H, Gao G,
Chen B, Liu Q, Shao C and Gong Y: Serum withdrawal up-regulates
human SIRT1 gene expression in a p53-dependent manner. J Cell Mol
Med. 13:4176–4184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li YG, Zhu W, Tao JP, Xin P, Liu MY, Li JB
and Wei M: Resveratrol protects cardiomyocytes from oxidative
stress through SIRT1 and mitochondrial biogenesis signaling
pathways. Biochem Biophys Res Commun. 438:270–276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lou Y, Wang Z, Xu Y, Zhou P, Cao J, Li Y,
Chen Y, Sun J and Fu L: Resveratrol prevents doxorubicin-induced
cardiotoxicity in H9c2 cells through the inhibition of
endoplasmicreticulum stress and the activation of the Sirt1
pathway. Int J Mol Med. 36:873–880. 2015.PubMed/NCBI
|
